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consisted of 2 steps. First, time-varying weights were estimated using multivariate 
logistic regression, including age, gender, stage, M-protein type, creatinine-clearance 
as baseline covariates and M-protein as time-varying covariate. In a second step, 
these time-dependent weights were incorporated in a proportional hazards model, 
including the same baseline characteristics, with patients censored at initiation of 
subsequent therapy. Results: 338/344 patients received up to nine 6-week cycles of 
VMP or MP respectively, with median follow-up of 44.2 months. 68% of MP-patients 
received subsequently therapy, compared to 58% in the VMP-arm. Age< 75, creati-
nine-clearance 30-60ml/min, stage III, and increasing M-protein measures over time 
were additional drivers for treatment-switching. The IPCW-approach generated an 
adjusted hazard ratio of 0.584 [0.406, 0.839], compared to the ITT-estimate of 0.704 
[0.576, 0.860]. ConClusions: In oncology, particularly in early line treatment, it is 
common that patients receive subsequent treatment lines. This typically happens 
more frequently and earlier in the comparator arm, which may bias the estimate for 
the treatment effect on OS. The IPCW-approach was explored to adjust for this bias, 
which resulted in an increased estimate of the treatment-effect on OS of VMP vs 
MP, compared to the original ITT-analysis. With overall survival being a key input in 
economic evaluation, estimating the accurate effect on OS is key. Employing this type 
of approaches may result in more accurate cost effectiveness results and thus more 
consistent/appropriate Health Technology Assessment recommendations.
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objeCtives: To explore the sharing of information across multiple studies in order to 
inform the choice of functional form when conducting parametric survival analysis.  
Methods: A set of four clinical trials in advanced soft tissue sarcoma were identi-
fied from a published systematic review. Individual patient data for overall survival 
were estimated from digitised Kaplan-Meier curves using a published algorithm. 
A range of parametric survival models (exponential, Weibull, Gompertz, log-nor-
mal, log-logistic, Gamma and Generalised Gamma) were fitted. Two approaches 
were explored for identifying the preferred parametric model: (i) selecting models 
independently for each study (ii) selecting a common model across all the studies. 
Models were selected using the Bayesian Information Criterion (BIC). For approach 
(ii) a single BIC statistic was calculated by summing the components of the BIC (n, 
k and ln (L)) across studies. Estimates of mean survival were derived for each model 
and a bootstrap analysis was conducted to estimate both the uncertainty in model 
selection and the variance in mean survival estimates. Results: Independent 
selection led to different functional forms being selected for each study with con-
siderable uncertainty regarding the choice of model (the bootstrap estimation for 
the probability that the optimum model had been selected varied between 16 to 84% 
across studies). The choice of model influenced mean survival predictions. Selecting 
a common model across studies was found to reduce the uncertainty in model 
selection and variance of the estimated mean survival (by up to 65%) compared to 
selecting models independently. ConClusions: Use of multiple studies to inform 
choice of functional form can improve the efficiency of survival estimates and hence 
reduce uncertainty of cost-effectiveness estimates. Given the considerable uncer-
tainty in selecting survival models within individual studies, it may be reasonable 
to treat information on functional form as exchangeable between studies and to 
‘borrow’ strength across studies.
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objeCtives: Combination statin therapy may help to further lower low-density 
lipoprotein cholesterol (LDL-C) better than monotherapy alone. The objective of this 
study was to apply predictive modeling methodology to determine the predictors of 
success and failure in achieving LDL-C goals after combination statin-fibrate therapy 
in patients diagnosed with hypertriglyceridemia (HTG). Methods: A large claims 
database was used to identify patients initiating a fibrate between January 2011 and 
December 2011 (index date). Diagnosis of HTG and the use of statins were confirmed 
within 6 months before the index date. A total of 622 patients were selected for the 
current analysis. Patients were categorized into very high risk, high risk, moderate 
risk, and low risk groups. Logistic regression and two-group discriminant analysis 
models based on 17 potential predictors for treatment success or failure were con-
structed. Results: At index, the median triglyceride (TG) level among all patients 
was 95.5 mg/dL, LDL-C level was 92 mg/dL, and high-density lipoprotein (HDL) was 
40 mg/dL. The mean age was 54 years. Two predictors were associated with combina-
tion statin-fibrate treatment success or failure and accounted for 5.3% of variance 
between groups. Low HDL (defined as < 40 mg/dL) (OR= 0.35; 95% CI, 0.20-0.59) and 
peripheral arterial disease (OR= 0.10; 95% CI, 0.02-0.38) were significantly associated 
with treatment failure. Low HDL variable was the key discriminator. ConClusions: 
Analytic insights enabled by predictive models may help researchers gain infor-
mation on discriminating factors about certain target treatment groups and drug 
classes. A set of key predictors may suggest opportunities to understand and predict 
treatment success and failure of targeted groups and/or drug classes. These predic-
tors may be useful in developing treatment strategies that will optimize outcomes.
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and 0.87 [0.68, 1.11] vs 0.655 [0.455, 0.944], respectively. ConClusions: This analysis 
shows the improved survival of patients who received novel therapies as compared 
to conventional therapies, across the different therapy lines. Additionally, results 
illustrate the impact of selection bias induced by selective treatment switching, and 
the need to apply novel approaches as IPCW to make additional adjustments, for 
which traditional statistical techniques cannot be used for.
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objeCtives: Despite significant patient heterogeneity and complex treatment 
pathways, averages are commonly relied upon when defining patient populations 
and treatment effects within type 2 diabetes modeling. As a result, clinicians may 
struggle to relate results to the clinical setting. This study compares outcomes 
when using patient-level and average cohort inputs within a published simulation 
model, based on the UKPDS68 outcomes equations. Methods: UK patient data 
(2,251 patients initiating dual therapy) were obtained from The Health Improvement 
Network (THIN). Simulations, performed over a medium-term horizon of 20 years, 
utilised either patient-level data, collating outputs over all replications, or average 
cohort data. The outputs (total costs, benefits and complication rates) were then 
compared. Results: Average baseline characteristics were: age: 63.36 (±11.14) years; 
HbA1c: 8.39% (±1.23); total cholesterol: 4.18 (±0.92) mmol/L; systolic blood pressure: 
135.07 (±14.76) mmHg; weight: 89.85 (±19.01) kg. The mean treatment effect was 
a reduction in HbA1c of 1.01 (±1.23) %. Over 20 years, fewer macrovascular and 
microvascular events (-82/1,000 patients) and higher all-cause mortality (+17/1,000 
patients) were predicted when using patient-level data compared to the average pro-
file. Differences in the frequency and timing of deaths were driven primarily by vari-
ation in age and led to fewer estimated life-years (-0.66), quality-adjusted life-years 
(QALYs; -0.59) and costs (-£551) per patient. Patients estimated to have lower costs 
and higher QALYs than those associated with the average profile were younger, with 
higher HbA1c and cholesterol but lower blood pressure at baseline. ConClusions: 
Modelling results differ depending on the use of patient-level or average cohort 
model inputs. Patient-level data may provide insight into the type of patients in 
whom therapy is likely to be most beneficial. Furthermore, it enables the accurate 
simulation of correlation between patient characteristics and treatment effect, 
which are rarely accounted for as part of a standard probabilistic sensitivity analysis.
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objeCtives: Previous studies have demonstrated incorporating parameter sam-
pling (PS) is crucial to capture nonlinear effects (NE) in cost effectiveness modeling. 
NE are, among other causes, driven by the degree through which the symmetric 
sampling of a risk factor is translated into non-symmetrically distributed prob-
abilities generated by the applied risk equations (RE). This study sought to assess 
degree by which the incorporation of NE through PS alters event rate predictions 
from the UKPDS 82 (UK82) and UKPDS 68 (UK68) RE in a set of selected validation 
studies conducted with the CDM. Methods: A total of 50 validation simulations 
were performed to data from ACCORD, ADVANCE, VADT, ASPEN, DCCT and UKPDS. 
Simulations mirroring cohort baseline characteristics of each of the trials were 
conducted with and without PS using UK68 and UK82 REs. Predicted versus observed 
macrovascular (MAC) and microvascular (MIC) complications and all cause mortal-
ity (ACM) were assessed using the coefficient of determination (R2) goodness of fit 
measure. Results: When the CDM was run without PS, validation studies produced 
an R2 statistic of 0.898 using UK68 and 0.853 using UK82 RE. This compared to R2 
statistics of 0.876 and 0.791 in analysis with PS for UK68 and UK 82 REs, respectively. 
Overall, PS caused end point predictions for MAC, MIC and ACM to increase. Internal 
validations against UKPDS 80 demonstrated that PS increased event rate predic-
tions for myocardial infarction (MI), stroke, MIC and ACM by 4.4%, 21.5%, 19% and 
16.4% when UK68 RE were applied and 26.3%, 64.7%, 14.9% and 34.8% with UK82 RE, 
respectively. ConClusions: The findings from this study have shown that external 
validity declined with PS in simulations using UK68 RE and UK82 RE. The degree 
by which PS increased end point predictions was considerable stronger in UK82 RE 
predictions for MAC and ACM but lower for MIC.
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objeCtives: ITT-analyses of oncology trials tend to underestimate the treatment 
effect on overall survival, due to the impact of subsequent therapy. Inverse probability 
of censoring weighted analysis (IPCW) was explored to estimate an adjusted treat-
ment effect on OS in VISTA, a phase III randomized clinical trial comparing melphalan 
and prednisone with or without bortezomib (VMP vs MP) in previously untreated mul-
tiple myeloma patients ineligible for stem cell transplantation. Methods: The IPCW 
